WILLIAMS AND JENSEN, PLLC for MERCK & CO INC
What was lobbied
7 issue areas, each in the filer's own words, with who lobbied on it and where.
Animals ANI
Monitor issues as they relate to animal health . Issues concerning the Animal Drug User Fee Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SCOTT GRAVES | Deputy Chief of Staff, Rep Conaway; COS, Rep Farenthold, COS, Rep Conaway; Staff Director, House Ag Committee |
| CHERYL LYNN JAEGER | Shrd employee, Ofc of the Speaker & Ofc of VA 7; Sr Plicy Adv, Maj Leader, Rep Cantor; Sr. Policy Adv, Rep Whip, Rep Cantor; Sr. Policy Adv, Maj Whip, Rep Blunt; Prof Staff House Committee on E&C; Sr LA to Rep Cox |
| KARINA LYNCH | Staff, Senate Special Committee on Aging; Staff, Senate Committee on Government Affairs; Senate Committees on Aging and Gov Affairs. |
| MATTHEW S VALESKO | — |
Trade (domestic/foreign) TRD
International trade issues and agreements; Monitor pending trade issues. Issues related to pharmaceutical manufacturing and development.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER W HATCHER | — |
| SUSAN HIRSCHMANN | COS, Rep Van Hilleary and Majority Whip |
| MATTHEW B HOEKSTRA | — |
| CHERYL LYNN JAEGER | Shared employee, Ofc of the Speaker & Ofc of VA 07; Sr Policy Adv, Maj Leader, Rep. Cantor; Sr Policy Adv, Republican Whip, Rep. Cantor; Sr Policy Adv, Majority Whip, Rep. Blunt; Prof Staff House Committee on E & C; Sr LA to Rep. Cox |
| KARINA LYNCH | — |
Defense DEF
Issues related to pharmaceutical manufacturing and development.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SUSAN HIRSCHMANN | COS, Rep Van Hilleary and Majority Whip |
| MATTHEW B HOEKSTRA | — |
| CHERYL LYNN JAEGER | Shrd employee, Ofc of the Speaker & Ofc of VA 07; Sr. Policy Adv, Maj Leader, Rep Cantor; Sr Policy Adv, Rep Whip, Rep Cantor; Sr. Policy Adv, Maj Whip, Rp Blunt; Prof Staff House Committee on E&C; Sr LA to Rep Cox |
| KARINA LYNCH | Staff, Senate Special Committee on Aging; Staff, Senate Committee on Government Affairs; Senate Committees on Aging and Gov Affairs |
Taxation/Internal Revenue Code TAX
Issues related to corporate tax including international tax proposals: Implementation of the Tax Cuts and Jobs Act (P.L. 115-97).
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER W HATCHER | — |
| SUSAN HIRSCHMANN | COS, Rep Van Hilleary and Majority Whip |
| CHERYL LYNN JAEGER | — |
| KARINA LYNCH | — |
Health Issues HCR
Drug safety; Congressional oversight issues; Issues related to vaccines and drug pricing; Drug pricing under 340B program; General education about FDA approval policies. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136. Education regarding Executive Orders impacting drug pricing including Medicare rebate reform, the 340 B program, "buy America" proposals, and proposals to impose "most favored nation" pricing on Medicare Part B and D; and H.R. 133, Consolidated Appropriations Act, 2021, Public Law No: 116-260.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SUSAN HIRSCHMANN | — |
| CHERYL LYNN JAEGER | — |
| KARINA LYNCH | — |
Medicare/Medicaid MMM
Payment policies for Part B prescription drugs; Rebates and co-pays for Medicare Part D drug benefits; Possible revisions in structure and operation of Medicare and Medicaid drug policies. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136. Education regarding Executive Orders impacting drug pricing including Medicare rebate reform, the 340 B program, "buy America" proposals, and proposals to impose "most favored nation" pricing on Medicare Part B and D; and H.R. 133, Consolidated Appropriations Act, 2021, Public Law No: 116-260.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SUSAN HIRSCHMANN | — |
| MATTHEW B HOEKSTRA | — |
| CHERYL LYNN JAEGER | Shared employee, Ofc of the Speaker and Ofc of VA 7th; Sr Policy Advisor, Majority Leader, Rep. Eric Cantor; Sr. Advisor, Majority Whip, Rep Roy Blunt; Prof Staff House Committee on E&C; Sr LA to Rep. Christopher Cox |
| KARINA LYNCH | — |
Budget/Appropriations BUD
Policies impacting Medicare Part D. Drug Development and Public Health Preparedness. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136; and H.R. 133, Consolidated Appropriations Act, 2021, Public Law No: 116-260.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SUSAN HIRSCHMANN | COS, Rep Van Hilleary and Majority Whip |
| MATTHEW B HOEKSTRA | — |
| CHERYL LYNN JAEGER | Shrd employee, Ofc of the Speaker & Ofc of VA 7;Sr policy adv, Maj Leader, Rep Cantor; Sr. Policy Adv, Rep Whip, Rep Cantor; Sr. Policy Adv, Maj Whip, Rep Blunt; Prof Staff House Committee on E&C; Sr. LA to Rep Cox |
| KARINA LYNCH | Staff, Senate Special Committee on Aging; Staff, Senate Committee on Government Affairs; Senate Committees on Aging and Government Affairs |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.